IL291864A - Combinations of cannabinoids and acyl-ethanol-amines - Google Patents
Combinations of cannabinoids and acyl-ethanol-aminesInfo
- Publication number
- IL291864A IL291864A IL291864A IL29186422A IL291864A IL 291864 A IL291864 A IL 291864A IL 291864 A IL291864 A IL 291864A IL 29186422 A IL29186422 A IL 29186422A IL 291864 A IL291864 A IL 291864A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- salt
- cannabinoid
- acylethanolamine
- pea
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154144P | 2015-04-29 | 2015-04-29 | |
| PCT/IL2016/050414 WO2016174661A1 (en) | 2015-04-29 | 2016-04-19 | Combinations of cannabinoids and n-acylethanolamines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291864A true IL291864A (en) | 2022-06-01 |
Family
ID=57199061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291864A IL291864A (en) | 2015-04-29 | 2016-04-19 | Combinations of cannabinoids and acyl-ethanol-amines |
| IL255238A IL255238B (en) | 2015-04-29 | 2017-10-24 | Combinations of cannabinoids and n-acylethanolamines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255238A IL255238B (en) | 2015-04-29 | 2017-10-24 | Combinations of cannabinoids and n-acylethanolamines |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US11234956B2 (enExample) |
| EP (2) | EP3288553B1 (enExample) |
| JP (2) | JP6938465B2 (enExample) |
| CN (2) | CN116549437A (enExample) |
| AU (3) | AU2016254685B2 (enExample) |
| CA (1) | CA2984088C (enExample) |
| DK (1) | DK3288553T3 (enExample) |
| ES (1) | ES2935605T3 (enExample) |
| IL (2) | IL291864A (enExample) |
| MA (1) | MA41997A (enExample) |
| PL (1) | PL3288553T3 (enExample) |
| WO (1) | WO2016174661A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3288553T3 (pl) * | 2015-04-29 | 2023-03-20 | Scisparc Ltd | Połączenia kannabinoidów i n-acyloetanoloamin |
| WO2019136351A1 (en) * | 2018-01-05 | 2019-07-11 | Altus Labs, Llc | Personal care compositions |
| CA3126772A1 (en) * | 2018-01-29 | 2019-08-01 | Evero | Compositions and methods for treating obstructive sleep apnea |
| MX2020010424A (es) * | 2018-04-03 | 2021-01-15 | Pure Green Pharmaceuticals Inc | Comprimido o composicion que contiene n-acil etanolamina y cannabinoides. |
| WO2020160452A1 (en) * | 2019-02-01 | 2020-08-06 | Tess Ventures, Inc. | Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies |
| WO2020214569A1 (en) | 2019-04-15 | 2020-10-22 | Metagenics, Inc. | Novel hemp and pea formulation and its use |
| US20220211647A1 (en) * | 2019-04-23 | 2022-07-07 | SciSparc Ltd. | Compositions and methods for potentiating derivatives of 4-aminophenols |
| WO2020227440A1 (en) * | 2019-05-07 | 2020-11-12 | Ojai Energetics Pbc | Methods for optimized cannabinoid dosage determination |
| WO2020237247A1 (en) | 2019-05-23 | 2020-11-26 | India Globalization Capital, Inc. | Compositions and methods using cannabinoids for treating stammering/stutering and symptoms of tourette syndrome |
| EP4017486A4 (en) * | 2019-08-19 | 2023-09-20 | Buzzelet Development And Technologies Ltd | COMPOSITIONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND THEIR USES |
| EP3838346A1 (en) * | 2019-12-20 | 2021-06-23 | Chemo Research SL | Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid |
| CN115297854A (zh) | 2020-01-10 | 2022-11-04 | 帕西拉制药股份有限公司 | 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛 |
| WO2021141959A1 (en) | 2020-01-10 | 2021-07-15 | Pacira Pharmaceuticals, Inc. | Treatment of pain by administration of sustained-release liposomal anesthetic compositions |
| US11273122B2 (en) | 2020-02-11 | 2022-03-15 | Therese Mainella | Combination of cannabis, derivatives thereof and additives in oral care compositions |
| EP4274573A4 (en) | 2021-01-11 | 2024-12-11 | Pacira Pharmaceuticals, Inc. | TREATMENT OF HIP PAIN WITH LIPOSOMAL SUSTAINED-RELEASE ANESTHESIA COMPOSITIONS |
| US20230000936A1 (en) * | 2021-06-30 | 2023-01-05 | Demetrix, Inc. | Alleviation of itching sensations using cannabinoid compounds |
| WO2023039419A2 (en) | 2021-09-08 | 2023-03-16 | Plantible Foods Inc. | Systems and methods for measuring mat density of aquatic biomass |
| WO2023200906A1 (en) | 2022-04-12 | 2023-10-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
| US12226610B2 (en) | 2022-11-03 | 2025-02-18 | Pacira Pharmaceuticals, Inc. | Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions |
| US11918565B1 (en) | 2022-11-03 | 2024-03-05 | Pacira Pharmaceuticals, Inc. | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
| WO2024124354A1 (en) * | 2022-12-16 | 2024-06-20 | Aima Inc. | Compositions and methods for treating or preventing pain or other disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU776414B2 (en) * | 1998-05-29 | 2004-09-09 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| GB2394894B (en) * | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
| US20090054526A1 (en) * | 2005-07-14 | 2009-02-26 | Hansen Harald S | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| GB2432312A (en) * | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
| PL2475352T5 (pl) * | 2009-09-07 | 2019-02-28 | Epitech Group S.P.A. | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| GB2495118B (en) * | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
| PL3288553T3 (pl) * | 2015-04-29 | 2023-03-20 | Scisparc Ltd | Połączenia kannabinoidów i n-acyloetanoloamin |
-
2016
- 2016-04-19 PL PL16786064.2T patent/PL3288553T3/pl unknown
- 2016-04-19 MA MA041997A patent/MA41997A/fr unknown
- 2016-04-19 AU AU2016254685A patent/AU2016254685B2/en active Active
- 2016-04-19 EP EP16786064.2A patent/EP3288553B1/en active Active
- 2016-04-19 CA CA2984088A patent/CA2984088C/en active Active
- 2016-04-19 US US15/570,118 patent/US11234956B2/en active Active
- 2016-04-19 CN CN202310678191.6A patent/CN116549437A/zh active Pending
- 2016-04-19 WO PCT/IL2016/050414 patent/WO2016174661A1/en not_active Ceased
- 2016-04-19 CN CN201680024534.5A patent/CN107530317A/zh active Pending
- 2016-04-19 IL IL291864A patent/IL291864A/en unknown
- 2016-04-19 JP JP2018507796A patent/JP6938465B2/ja active Active
- 2016-04-19 DK DK16786064.2T patent/DK3288553T3/da active
- 2016-04-19 ES ES16786064T patent/ES2935605T3/es active Active
- 2016-04-19 EP EP22215663.0A patent/EP4193993A3/en active Pending
-
2017
- 2017-10-24 IL IL255238A patent/IL255238B/en unknown
-
2019
- 2019-08-30 US US16/557,379 patent/US11207290B2/en active Active
- 2019-10-01 US US16/589,611 patent/US20200030281A1/en not_active Abandoned
- 2019-10-10 US US16/598,029 patent/US11197845B2/en not_active Expired - Fee Related
-
2021
- 2021-03-30 JP JP2021057991A patent/JP2021107401A/ja active Pending
- 2021-07-19 AU AU2021206784A patent/AU2021206784B2/en active Active
- 2021-08-27 US US17/459,583 patent/US20210393577A1/en active Pending
- 2021-11-12 US US17/524,942 patent/US20220071948A1/en not_active Abandoned
- 2021-11-12 US US17/525,046 patent/US20220071949A1/en active Pending
-
2023
- 2023-10-17 AU AU2023251426A patent/AU2023251426B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291864A (en) | Combinations of cannabinoids and acyl-ethanol-amines | |
| FI3743053T3 (fi) | Kannabinoidien käyttö epilepsian hoidossa | |
| FI3641819T3 (fi) | Kannabidiolin käyttö tuberoosisklerooosikompleksin hoitoon | |
| MX2021008702A (es) | Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia. | |
| EP2609928A3 (en) | Use of cannabinoids in combination with an anti-psychotic medicament | |
| FI3710058T3 (fi) | Kannabidiolin käyttö lamotrigiinin lisäksi kohtausten hoitoon, jotka liittyvät Lennox-Gastaut-oireyhtymään | |
| MX2020003934A (es) | Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia. | |
| WO2009043395A3 (en) | Pharmaceutical composition | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2020005719A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| GB201116789D0 (en) | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd) | |
| GB201111261D0 (en) | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | |
| PE20200677A1 (es) | Composicion de cannabis | |
| MX387442B (es) | Composiciones y tratamientos para el trastorno del sueño | |
| JP2010524912A5 (enExample) | ||
| JP2009539961A5 (enExample) | ||
| WO2007124489A3 (en) | Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines | |
| CA2582289C (en) | Inhibition of tumour cell migration | |
| EP2782563B1 (en) | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases | |
| Cai et al. | Regulation of the Notch signaling pathway by natural products for cancer therapy | |
| WO2022167822A3 (en) | A cannabinoid mixture | |
| RU2020115363A (ru) | Каннабиноидная композиция и способ ее применения | |
| GEP20115218B (en) | Combination drug | |
| WO2008113100A1 (en) | Method for inducing autophagy | |
| RU2011129815A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи |